Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States. Electronic address: https://twitter.com/GCattaneoPhD.
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Cancer Lett. 2024 Apr 10;587:216713. doi: 10.1016/j.canlet.2024.216713. Epub 2024 Feb 14.
Human leukocyte antigen (HLA) class I defects are associated with cancer progression. However, their prognostic significance is controversial and may be modulated by immune checkpoints. Here, we investigated whether the checkpoint B7-H3 modulates the relationship between HLA class I and pancreatic ductal adenocarcinoma (PDAC) prognosis. PDAC tumors were analyzed for the expression of B7-H3, HLA class I, HLA class II molecules, and for the presence of tumor-infiltrating immune cells. We observed defective HLA class I and HLA class II expressions in 75% and 59% of PDAC samples, respectively. HLA class I and B7-H3 expression were positively related at mRNA and protein level, potentially because of shared regulation by RELA, a sub-unit of NF-kB. High B7-H3 expression and low CD8 T cell density were indicators of poor survival, while HLA class I was not. Defective HLA class I expression was associated with unfavorable survival only in patients with low B7-H3 expression. Favorable survival was observed only when HLA class I expression was high and B7-H3 expression low. Our results provide the rationale for targeting B7-H3 in patients with PDAC tumors displaying high HLA class I levels.
人类白细胞抗原(HLA)I 类缺陷与癌症进展有关。然而,其预后意义存在争议,并且可能受到免疫检查点的调节。在这里,我们研究了检查点 B7-H3 是否调节 HLA I 类与胰腺导管腺癌(PDAC)预后之间的关系。分析了 PDAC 肿瘤中 B7-H3、HLA I 类、HLA II 类分子的表达以及肿瘤浸润免疫细胞的存在情况。我们观察到 75%的 PDAC 样本存在 HLA I 类表达缺陷,59%的 PDAC 样本存在 HLA II 类表达缺陷。HLA I 类和 B7-H3 的表达在 mRNA 和蛋白水平上呈正相关,这可能是由于 RELA(NF-kB 的一个亚基)的共同调节。高 B7-H3 表达和低 CD8 T 细胞密度是预后不良的指标,而 HLA I 类则不是。HLA I 类表达缺陷仅与 B7-H3 表达低的患者的不良生存相关。仅当 HLA I 类表达高且 B7-H3 表达低时,才观察到有利的生存。我们的研究结果为在 HLA I 类水平高的 PDAC 肿瘤患者中靶向 B7-H3 提供了依据。